Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study

Hee Jeong Lee 1, Haekyung Lee 1, Song Hee Oh 1, Suyeon Park 2, Kwang-Young Jung 2, Hyoungnae Kim 1,3, Soon Hyo Kwon 1,3, Jin Seok Jeon 1,3, Dong Cheol Han 1,3 and Hyunjin Noh 1,3,*

1 Division of Nephrology, Department of Internal Medicine, Soon Chun Hyang University, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea
2 Department of Biostatistics, Soon Chun Hyang University Seoul Hospital, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea
3 Hyonam Kidney Laboratory, Soon Chun Hyang University, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea
* Correspondence: nohneph@schmc.ac.kr; Tel.: +82-2-709-9198; Fax: +82-2-792-5812

Received: 25 June 2019; Accepted: 29 July 2019; Published: 31 July 2019

Abstract: Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The β2AR agonist group was divided into quartiles according to the duration of β2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75–0.86, p < 0.001) in the longest quartile of β2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of β2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthalmic complications was consistent, and the risks were significantly lower in the longest users than the control group. Long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications.

Keywords: diabetes; vascular complications; beta2-adrenergic receptor; macrophages

1. Introduction

Diabetes is associated with multiple vascular diseases that affect almost every arterial vascular bed [1]. Proatherogenic changes in diabetic patients include increases in vascular inflammation and derangements in the cellular components of the vasculature, most notably, endothelial cells and vascular smooth muscle cells [1]. Although the pathophysiology is not fully understood, macrophages are known to be significantly involved in this inflammatory process [2,3]. Previous studies have reported an association between macrophage differentiation and diabetic retinopathy [4], nephropathy [5], and coronary vascular diseases [2]. As a result, adults with diabetes have a two- to three-fold increased risk of a wide range of vascular diseases, including coronary heart disease and stroke [6]. Moreover, the odds ratios for diabetic patients with chronic kidney disease (CKD) vary by region between 1.3 and 4.6 [7].
Beta2-adrenergic receptor (β2AR) agonists are bronchodilators commonly used to treat bronchial asthma, chronic obstructive pulmonary disease (COPD), and other respiratory infections. β2AR agonists target and activate β2ARs to stimulate their downstream cascades, which mediate numerous airway functions by regulating bronchoconstriction and dilation pathways. β2AR agonists are very commonly used clinically and mainly lead to nonfatal complications such as headache, dizziness, and muscle cramps [8] without serious adverse effects.

In our own previous study, we identified β2AR agonists as the most potent anti-inflammatory drug in a multidrug screening analysis [9]. We confirmed their anti-inflammatory actions through multiple observations, including their inhibition of phorbol myristate acetate and lipopolysaccharide-induced tumor necrosis factor alpha (TNF-α) production in rat bone marrow macrophages, diabetes-induced TNF-α production in peripheral blood mononuclear cells from streptozotocin-induced diabetic rats, and macrophage infiltration in the kidneys and heart of Zucker diabetic fatty rats. Their mechanism of action involves inhibition of the nuclear factor κB (NF-κB) signal pathway by enhancing β-arrestin2 and its interaction with inhibitor of NF-κBα. From this study, we inferred that β2AR agonists might have preventive effects against vascular complications in diabetic patients. However, clinical studies demonstrating these anticipated effects of β2AR agonists have not yet been published. Our objective in this study was to determine whether β2AR agonists effectively inhibit macro- and microvascular complications in patients with diabetes.

2. Experimental Section

2.1. Study Design and Participants

This study cohort was comprised of Korean patients who were first diagnosed with diabetes in 2004 (n = 249,222). We defined this group as patients aged ≥20 years who received diagnostic codes for diabetes in 2004 along with more than two prescriptions for diabetes-related medications. To clarify the definition of new-onset diabetes, we excluded patients with diabetes codes within the previous two years (2002–2003). We also excluded patients who had diabetes codes but did not take antidiabetic medication or received such medications only once, because we could not be sure that these patients were truly diabetic. Patients with vascular complications due to diabetes at the time of enrollment were also excluded.

We divided the participants into two groups: the β2AR agonist group, including patients who received prescriptions for systemic β2AR agonists (oral administration) more than twice in 2004, and the control group including patients who did not take β2AR agonists during the study period (2004–2015). Systemic β2AR agonists included short-acting β2AR agonists (SABA), i.e., fenoterol, procaterol, salbutamol, terbutaline or long-acting β2AR agonists (LABA), i.e., bambuterol, formoterol, clenbuterol. To reduce confusion, we excluded patients who received prescriptions of systemic β2AR agonists only once in 2004 and patients who did not take systemic β2AR agonists in 2004 but received them later in the study period. In addition, patients who took β2AR agonists but died during the first two years of the study period (2004–2005) were excluded because those deaths were considered unrelated to the β2AR agonists. All subsequent deaths were registered in the study. In the end, we excluded 213,828 of the original (n = 249,222) participants, leaving a total of 35,245 (β2AR agonist group, n = 5179 and control group, n = 30,066).

We performed 1:1 matching using the propensity score matching method to ensure equivalence in sex, age, history of hypertension, hyperlipidemia, COPD, and asthma. History of hypertension or hyperlipidemia were defined as patients with the diagnostic codes for hypertension or hyperlipidemia, with corresponding medications prescribed more than twice per year during 2002–2004. A total of 5179 patients were included in each group and observed until 31 December 2015. No other clinical information about the patients was provided. After the 1:1 matching, the β2AR agonist group was classified into quartiles and analyzed according to the duration of β2AR agonist use. The flow chart of this study is shown in Figure 1.
Figure 1. Flow chart of the study population. From the 249,222 participants initially enrolled, 213,828 patients were excluded. After 1:1 matching using propensity score matching, each group contained 5179 participants. Abbreviation: β2AR, beta2-adrenergic receptor.

2.2. Data Source and Ethics Statement

Data were extracted from the Korean National Health Insurance Service (KNHIS). All Koreans are registered in the KNHIS database, which has covered the entire population as a compulsory social insurance scheme since 1989 and is regulated by the Ministry of Health and Welfare [10]. Consequently, a large amount of health-related data has been accumulated in the KNHIS database, including data on demographic factors (age, sex, residential area, and socioeconomic variables such as type of health insurance) and medical factors (diagnosis codes, history of procedures or surgeries, and drug prescriptions). The KNHIS stores and manages the data and provides the data for research purposes [11]. More details about KNHIS have been provided elsewhere [10]. In the case of a disease covered by insurance in Korea, all clinicians must enter the diagnosis code and their prescriptions. Patient diagnoses are based on the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10-CM) diagnostic and procedure codes. We extracted the data as a custom sample, using the proposed conditions, i.e., patients diagnosed with diabetes in 2004.

This study protocol was approved by the institutional review board (IRB) of the Soon Chun Hyang University Seoul Hospital (IRB number 2017-05-001) and conducted in accordance with the Declaration of Helsinki. This was an anonymous observational study, so the need for informed consent was waived.

2.3. Outcome Measurements

The primary outcome was the occurrence of diabetic vascular complications. Complications were classified into two major categories of macro- and microvascular complications. Macrovascular complications included cardiovascular, cerebrovascular, and peripheral vascular complications; microvascular complications included peripheral neuropathy and renal and ophthalmic complications. Cardiovascular complications were defined as patients with diagnostic codes corresponding to coronary disease and its complications. Heart failure resulting from other myopathies was excluded. Cerebrovascular complications included occlusion and stenosis of cerebrovascular structures and diagnostic codes for stroke, excluding hemorrhagic stroke. Peripheral vascular complications included atherosclerosis, stenosis, and occlusion of peripheral arteries, along with symptomatic diagnostic codes such as claudication. Diabetic ulcer disease was also included. Renal complications included CKD in all
stages, proteinuria including albuminuria, and end-stage renal disease. Peripheral neuropathy included diagnostic codes for various mono- and polyneuropathies that correspond to diabetic complications. Ophthalmic complications included various retinal and macular findings corresponding to diabetic complications, including neovascularization, aneurysm, edema, and hemorrhage.

Endpoints were assigned to each patient according to the diagnostic codes provided for complications. The disease-free survival time was calculated between the date of diabetes diagnosis and the date of diabetic complication diagnosis.

2.4. Statistical Analysis

To identify the effect of \( \beta 2 \)AR agonists, we used propensity score matching (Matchit in R package) to reduce the selection bias between groups. The unmatched variables (sex, age, hyperlipidemia, COPD, and asthma) were adjusted through multivariate analysis. A multivariate Cox proportional hazard regression analysis was performed by selecting factors with a significance level of less than 0.1 in the univariate analyses. Analysis was performed including the duration of \( \beta 2 \)AR agonist administration by dividing the \( \beta 2 \)AR agonist group into quartiles using the period (days) variable based on the number of \( \beta 2 \)AR agonist prescription days from enrollment in 2004 to the diagnosis of vascular complications. The Kaplan–Meier (KM) survival curve was plotted using SAS 9.3. All results were presented as a hazard ratio (HR) with a 95% confidence interval (CI). The level of significance was set at \( p < 0.05 \), and the tests were two-sided tests. All analyses were performed in SAS 9.3 and R v3.3.1.

3. Results

The baseline characteristics of the before and after matched groups are shown in Table 1. More female and elderly (aged \( \geq 60 \) years) patients and patients with COPD or asthma were included in the \( \beta 2 \)AR agonist group even after 1:1 matching using the propensity score matching method. Meanwhile, the number of patients with a history of hyperlipidemia was lower in the \( \beta 2 \)AR agonist group. We analyzed the diagnostic codes at the time of \( \beta 2 \)AR agonist prescription and found that acute bronchiolitis was the most common code, followed by asthma and allergic rhinitis.

| Variables          | \( \beta 2 \)AR Agonist Group (n = 5179) | Non-\( \beta 2 \)AR Agonist Group                                      | \( p \)-Value |
|--------------------|-----------------------------------------|---------------------------------------------------------------------|-------------|
|                    | Before Matching (n = 30,066) | After Matching (n = 5179) | Before | After |
| Sex                |                                        |                        | n      | %    | n      | %    | Before | After |<0.001 | 0.004 |
| Male               | 2577 | 49.8 | 21,320 | 70.9 | 2724 | 52.6 | <0.001 | 0.004 |
| Female             | 2602 | 50.2 | 8746   | 29.1 | 2455 | 47.4 | <0.001 | 0.001 |
| Age (years)        |                                        |                        | n      | %    | n      | %    | Before | After |<0.001 | <0.001 |
| 20–39              | 491  | 9.5  | 5057   | 16.8 | 596  | 11.5 | <0.001 | <0.001 |
| 40–59              | 2287 | 44.2 | 17,630 | 58.6 | 2375 | 45.9 |         |        |
| \( \geq 60 \)      | 2401 | 46.4 | 7379   | 24.5 | 2208 | 42.6 |         |        |
| Hypertension       |                                        |                        | n      | %    | n      | %    | Before | After |
| No                 | 2870 | 55.4 | 20,371 | 67.8 | 2882 | 55.6 | <0.001 | 0.812 |
| Yes                | 2309 | 44.6 | 9695   | 32.2 | 2297 | 44.4 | <0.001 | 0.005 |
| Hyperlipidemia     |                                        |                        | n      | %    | n      | %    | Before | After |
| No                 | 4381 | 84.6 | 26,261 | 87.3 | 4274 | 82.5 | <0.001 | 0.005 |
| Yes                | 798  | 15.4 | 3805   | 12.7 | 905  | 17.5 | <0.001 | 0.004 |
| COPD               |                                        |                        | n      | %    | n      | %    | Before | After |
| No                 | 3381 | 65.3 | 28,405 | 94.5 | 3518 | 67.9 | <0.001 | 0.004 |
| Yes                | 1798 | 34.7 | 1661   | 5.5  | 1661 | 32.1 | <0.001 | <0.001 |
| Asthma             |                                        |                        | n      | %    | n      | %    | Before | After |
| No                 | 2772 | 53.5 | 28,946 | 96.3 | 4059 | 78.4 | <0.001 | <0.001 |
| Yes                | 2407 | 46.5 | 1120   | 3.7  | 1120 | 21.6 |         |        |

Abbreviations: \( \beta 2 \)AR, beta2-adrenergic receptor; COPD, chronic obstructive pulmonary disease.

To determine the relationship between the occurrence of all vascular complications and the \( \beta 2 \)AR agonist administration along with its duration, we evaluated the incidence of all vascular complications within the \( \beta 2 \)AR agonist group according to the duration of \( \beta 2 \)AR agonist administration and then made comparisons between each of those groups and the control group. We classified the duration
of β2AR agonist administration into quartiles. The follow-up period varied between complications because each endpoint was set differently for each complication. Therefore, quartile values differed for each complication. When analyzing the HR, we used multivariate Cox proportional hazard regression analysis to adjust for the relevant factors, including those not fully matched to increase accuracy.

Upon Cox proportional hazard regression analysis by duration, the incidence of vascular complications significantly decreased with an increased duration of β2AR agonist use. The HRs for all vascular complications in quartiles 1 and 2 showed a higher risk of all vascular complications as compared with the non-β2AR agonist group (Table 2). However, in quartile 3, HR did not show any difference as compared with the non-β2AR agonist group. Furthermore, in quartile 4, the risk of all vascular complications was significantly reduced with an HR of 0.80 (95% CI, 0.75–0.86, p < 0.001). When analyzed separately for each vascular complication, cerebrovascular (HR 0.79; 95% CI, 0.69–0.89, p < 0.001), peripheral vascular (HR 0.82; 95% CI, 0.75–0.89, p < 0.001), peripheral nerve (HR 0.75; 95% CI, 0.67–0.83, p < 0.001), and ophthalmic complications (HR 0.88; 95% CI, 0.80–0.97, p = 0.008) all showed similar results, with all HRs in quartile 4 less than one. Of note, the risk of renal complications was significantly reduced as compared with the non-β2AR agonist group even in quartile 3 (HR 0.84; 95% CI, 0.74–0.96, p = 0.009). The risk of cardiovascular complications was qualitatively similar to that observed in the other complications except that the HR in quartile 4 did not achieve statistical significance (HR 0.90; 95% CI, 0.80–1.01, p = 0.068). The duration corresponding to quartile 4 was ≥42 days for all composite complications, ≥68 days for cerebrovascular complications, ≥55 days for peripheral vascular complications, and ≥62 days for peripheral nerve and ophthalmic complications. In terms of the renal complications, a protective effect was observed in the patients in quartile 3 who had been taking β2AR agonists for ≥28 days. The KM survival curves of these analyses are shown in Figure 2.

Table 2. Hazard ratios of vascular complications by duration of β2AR agonist administration in the β2AR agonist group.

|                | Univariate |            |         |          |            |         |          |            |         |          |            |         |          |
|----------------|------------|------------|---------|----------|------------|---------|----------|------------|---------|----------|------------|---------|----------|
|                | Period     | control    | reference | HR       | 95% CI     | p-Value | HR       | 95% CI     | p-Value |
|                | (days)     | Lower      | Upper    | p-Value  | Lower      | Upper    | p-Value  | Lower      | Upper    |          |            |         |          |
| All complications * |           | <8         | 1.52     | 1.42     | 1.63       | <0.001   | 1.56     | 1.46       | 1.67     | <0.001   | <8         | 1.52     | 1.42     | 1.63       | <0.001   |
|                |            | <17        | 1.29     | 1.21     | 1.37       | <0.001   | 1.30     | 1.22       | 1.38     | <0.001   | <17        | 1.29     | 1.21     | 1.37       | <0.001   |
|                |            | <42        | 1.06     | 1.00     | 1.13       | 0.069    | 1.10     | 0.95       | 1.08     | 0.740    | <42        | 1.06     | 1.00     | 1.13       | 0.069    |
|                |            | ≥42        | 0.92     | 0.87     | 0.99       | 0.021    | 0.80     | 0.75       | 0.86     | <0.001   | ≥42        | 0.92     | 0.87     | 0.99       | 0.021    |
| Cardiovascular complications † | Period     | control    | reference | HR       | 95% CI     | p-Value | HR       | 95% CI     | p-Value |
|                | (days)     | Lower      | Upper    | p-Value  | Lower      | Upper    | p-Value  | Lower      | Upper    |          |            |         |          |
|                | <11        | 1.65       | 1.50     | 1.82     | <0.001     | 1.72     | 1.56     | 1.90       | <0.001   |          |            |         |          |
|                | <25        | 1.34       | 1.21     | 1.48     | <0.001     | 1.32     | 1.19     | 1.45       | <0.001   |          |            |         |          |
|                | <67        | 1.11       | 1.00     | 1.24     | 0.046      | 1.04     | 0.93     | 1.15       | 0.05     |          |            |         |          |
|                | ≥67        | 1.16       | 1.05     | 1.29     | 0.005      | 0.90     | 0.80     | 1.01       | 0.068    |          |            |         |          |
| Cerebrovascular complications ‡ | Period     | control    | reference | HR       | 95% CI     | p-Value | HR       | 95% CI     | p-Value |
|                | (days)     | Lower      | Upper    | p-Value  | Lower      | Upper    | p-Value  | Lower      | Upper    |          |            |         |          |
|                | <12        | 1.46       | 1.31     | 1.62     | <0.001     | 1.55     | 1.39     | 1.73       | <0.001   |          |            |         |          |
|                | <26        | 1.12       | 1.00     | 1.25     | 0.045      | 1.11     | 0.99     | 1.24       | 0.066    |          |            |         |          |
|                | <68        | 1.04       | 0.93     | 1.17     | 0.483      | 0.96     | 0.85     | 1.07       | 0.440    |          |            |         |          |
|                | ≥68        | 1.07       | 0.95     | 1.20     | 0.281      | 0.79     | 0.69     | 0.89       | <0.001   |          |            |         |          |
| Peripheral vascular complications § | Period     | control    | reference | HR       | 95% CI     | p-Value | HR       | 95% CI     | p-Value |
|                | (days)     | Lower      | Upper    | p-Value  | Lower      | Upper    | p-Value  | Lower      | Upper    |          |            |         |          |
|                | <10        | 1.64       | 1.52     | 1.77     | <0.001     | 1.68     | 1.56     | 1.82       | <0.001   |          |            |         |          |
|                | <21        | 1.29       | 1.20     | 1.40     | <0.001     | 1.29     | 1.20     | 1.40       | <0.001   |          |            |         |          |
|                | <55        | 1.05       | 0.97     | 1.14     | 0.217      | 0.99     | 0.91     | 1.07       | 0.823    |          |            |         |          |
|                | ≥55        | 0.96       | 0.89     | 1.05     | 0.381      | 0.82     | 0.75     | 0.86       | <0.001   |          |            |         |          |
| Renal complications ¥ | Period     | control    | reference | HR       | 95% CI     | p-Value | HR       | 95% CI     | p-Value |
|                | (days)     | Lower      | Upper    | p-Value  | Lower      | Upper    | p-Value  | Lower      | Upper    |          |            |         |          |
|                | <12        | 1.54       | 1.38     | 1.73     | <0.001     | 1.54     | 1.37     | 1.72       | <0.001   |          |            |         |          |
|                | <27        | 1.03       | 0.92     | 1.16     | 0.601      | 1.01     | 0.90     | 1.14       | 0.869    |          |            |         |          |
|                | <72        | 0.87       | 0.77     | 1.00     | 0.041      | 0.84     | 0.74     | 0.96       | 0.009    |          |            |         |          |
|                | ≥72        | 0.81       | 0.70     | 0.92     | 0.002      | 0.75     | 0.65     | 0.86       | <0.001   |          |            |         |          |
Table 2. Cont.

| Univariate | Multivariate |
|------------|-------------|
|            | HR 95% CI   | p-Value | HR 95% CI   | p-Value |
|            | Lower | Upper | Lower | Upper |

**Peripheral nerve complications **

| Period (days) | control | reference | reference | reference | reference | reference |
|---------------|---------|-----------|-----------|-----------|-----------|-----------|
| <11           | 1.60    | 1.47      | 1.73      | <0.001    | 1.64      | 1.51      | 1.79      | <0.001    |
| <23           | 1.20    | 1.10      | 1.31      | <0.001    | 1.21      | 1.11      | 1.33      | <0.001    |
| <62           | 0.94    | 0.86      | 1.04      | 0.222     | 0.93      | 0.85      | 1.02      | 0.126     |
| ≤62           | 0.81    | 0.74      | 0.90      | <0.001    | 0.75      | 0.67      | 0.83      | <0.001    |

**Ophthalmic complications**

| Period (days) | control | reference | reference | reference | reference | reference |
|---------------|---------|-----------|-----------|-----------|-----------|-----------|
| <11           | 1.68    | 1.55      | 1.83      | <0.001    | 1.70      | 1.57      | 1.85      | <0.001    |
| <24           | 1.29    | 1.19      | 1.41      | <0.001    | 1.29      | 1.18      | 1.40      | <0.001    |
| <62           | 1.09    | 1.00      | 1.19      | 0.061     | 1.07      | 0.98      | 1.17      | 0.135     |
| ≤62           | 0.90    | 0.82      | 0.99      | 0.028     | 0.88      | 0.80      | 0.97      | 0.008     |

Abbreviations: β2AR, beta2-adrenergic receptor; HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease. * p-value adjusted by β2AR agonist, sex, age, hypertension, hyperlipidemia, COPD, and asthma. † p-value adjusted by β2AR agonist, age, hypertension, hyperlipidemia, COPD, and asthma. ‡ p-value adjusted by β2AR agonist, sex, age, hypertension, hyperlipidemia, COPD, and asthma. § p-value adjusted by β2AR agonist, hyperlipidemia, and COPD. ¶ p-value adjusted by β2AR agonist, sex, age, and hyperlipidemia. 

Figure 2. Cont.
Figure 2. Kaplan–Meier survival curves comparing the outcomes for (A) all vascular complications, (B) cardiovascular complications, (C) cerebrovascular complications, (D) peripheral vascular complications, (E) renal complications, (F) peripheral nerve complications, and (G) ophthalmic complications according to the duration of β2AR agonist administration. The duration of the β2AR agonist administration was classified into quartiles. Abbreviation: β2AR, beta2-adrenergic receptor.

4. Discussion

In this study, we found the occurrence of vascular complications of diabetic patients significantly decreased with an increased duration of β2AR agonist administration, and eventually the risks were significantly lower than those in the non-β2AR agonist group for the longest users.

In our previous report, a drug screen analysis revealed that β2AR agonists have an anti-inflammatory action that targets macrophage activation in diabetic animals, especially in the kidneys and heart [9]. While a few studies have reported β2AR agonists as potential therapeutics for diabetic vasculopathy [12–14] in animal models, to the best of our knowledge, no human trials have been reported. We conducted this study to examine the association between β2AR agonists and the outcomes of diabetic macro- and microvascular complications, and to investigate whether β2AR agonists exert protective effects against these complications clinically, as observed in animal studies.

β2AR agonists are commonly used in acute respiratory infections, COPD, and asthma, a prescription pattern that was confirmed in this study by our examination of the common diagnostic codes among patients who received β2AR agonists. The present study included oral β2AR agonists, which are grouped into SABA and LABA. In general, COPD and asthma are associated with a higher prevalence of vascular diseases [15]. In particular, COPD patients are nearly five times more likely to have a cardiovascular disease than individuals without COPD [16]. It is known that chronic persistent
inflammation in the respiratory tract and systemic circulation can stimulate inflammatory cells and modify various proteins, thereby activating atherosclerotic plaques and inducing a prothrombotic state [16]. Moreover, acute respiratory infections such as influenza or community-acquired pneumonia are also known to be associated with an increased risk of cardiovascular disease [17,18]. In a case-control study, recent respiratory infection has shown high associations with myocardial infarction (MI) and stroke; the odds ratio in the seven days following infection was 2.10 (1.38–3.21) for MI and 1.92 (1.24–2.97) for stroke [19]. In other words, most of the reasons for prescribing β2AR agonists are also common risk factors for cardiovascular diseases. In addition, it has been reported that COPD is associated with diabetic microvascular complications such as retinopathy [20], neuropathy [21], and CKD [22], although the associations between microvascular complications and acute respiratory infections remain unknown. Therefore, it is expected that the reasons for taking β2AR agonist are already the risk factors for various vascular complications. Our findings that the patients in the first or second quartile (short-term users) showed higher HRs as compared with the control group may be attributable to these findings. However, the important findings are that the risk of vascular complications gradually decreased with increasing duration of β2AR agonist administration and that the longest users in the fourth quartile showed a significantly reduced risk as compared to non-users. Given that the prolonged use of β2AR agonists is associated with sustained or severe disease activity due to COPD, asthma, or other respiratory infections, it is notable that the long-term use of β2AR agonists was associated with a significantly decreased incidence of all vascular complications as compared with the non-users. In fact, subjects in quartile 4 had a significantly higher prevalence of asthma and COPD and higher rates of elderly than the control group as shown in Supplementary Table S1. These findings suggest that the long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications.

Additional analysis of each macro- and microvascular complication also confirmed the gradual decrease in the HRs as the duration increased. The time to achieve the beneficial effect of β2AR agonists on the composite, cerebrovascular, peripheral vascular, renal, peripheral nerve, and ophthalmic complications was 42, 68, 55, 28, 62, and 62 days, respectively. Interestingly, it is likely that the protective effect of β2AR agonists is most powerful against renal complications, since the patients in quartile 3, as well as in quartile 4, showed a significantly lower risk of such complications than the control group.

In general, it is well established that diabetic patients with macrovascular complications often have coincident microvascular complications [23–25]. However, independent associations between vascular complications and their differential regulation remain unclear. A recent study suggested that there may be shared protective factors for proliferative retinopathy and cardiovascular disease but not kidney disease in type 1 diabetes [26]. Another study has also shown that the presence of coronary artery calcification in long-standing type 1 diabetic patients was associated with neuropathy and retinopathy but not with renal hemodynamic function [27]. In the present study, however, we did not observe significant differences in the effects of long-term use of β2AR agonists according to the type of vascular complications other than a temporal relationship in renal complications.

To our knowledge, this is the first study supporting the effect of β2AR agonists on various vascular complications in diabetic patients. This was a population-based cohort study [28] with a long-term follow-up of more than 10 years from the diagnosis of diabetes.

However, our study also has some limitations. First, there was an absence of clinical information regarding smoking status, alcohol consumption, and documented history of hypertension, hyperlipidemia, COPD, or asthma, as we used only diagnostic codes to infer medical history information. This is a limitation of big data analysis in general. We attempted to address this problem by recruiting only those patients to whom a drug relevant to the diagnostic codes was prescribed at least twice. Second, we had no information as to the cause of death, which might have facilitated a more accurate assessment. Finally, the main limitation of our study was that we only analyzed patients taking oral medication and did not include inhaler users because the number of puffs prescribed varied according
to the severity of symptoms, which made it difficult to confirm the exact duration of β2AR agonist use. This limitation may have caused the majority of β2AR agonist users to be excluded.

In conclusion, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased and, when taken for a sufficient period of time, the incidence was even lower than that in the control group. Our findings suggest that the long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications. Further studies including inhaler users and well-designed human trials are warranted to elucidate the impact of β2AR agonists on vascular complications.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/8/1145/s1, Table S1: Baseline characteristics of β2AR agonist group by duration.

Author Contributions: Conceptualization and design, collection and analysis of data, manuscript writing—original draft preparation, H.J.L.; writing—review and editing, H.L.; collection and analysis of data, S.H.O., S.P., and K.-Y.J.; interpretation of data and critical review of manuscript, H.K., S.H.K., J.S.J., and D.C.H.; conceptualization and design, financial support, interpretation of data, writing—review and editing and final approval of manuscript, H.N.

Funding: This work was supported by a National Research Foundation of Korea grant funded by the Korean government (2016R1D1A3B04933480) and the Soon Chun Hyang University Research Fund (to H.N.).

Acknowledgments: The authors thank Jae Heon Kim, Soon Chun Hyang University Seoul Hospital, for careful review.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Gibbons, G.W.; Shaw, P.M. Diabetic vascular disease: Characteristics of vascular disease unique to the diabetic patient. Semin. Vasc. Surg. 2012, 25, 89–92. [CrossRef] [PubMed]
2. Yahagi, K.; Kolodgie, F.D.; Lutter, C.; Mori, H.; Romero, M.E.; Finn, A.V.; Virmani, R. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 191–204. [CrossRef] [PubMed]
3. Nishizawa, T.; Bornfeldt, K.E. Diabetic vascular disease and the potential role of macrophage glucose metabolism. Ann. Med. 2012, 44, 555–563. [CrossRef] [PubMed]
4. Cui, X.; Kushiyama, A.; Yoneda, M.; Nakatsu, Y.; Guo, Y.; Zhang, J.; Ono, H.; Kanna, M.; Sakoda, H.; Ono, H.; et al. Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy. Diabetes Res. Clin. Pract. 2010, 87, 57–63. [CrossRef] [PubMed]
5. Wang, Z.; Wei, M.; Wang, M.; Chen, L.; Liu, H.; Ren, Y.; Shi, K.; Jiang, H. Inhibition of macrophage migration inhibitory factor reduces diabetic nephropathy in type II diabetes mice. Inflammation 2014, 37, 2020–2029. [CrossRef]
6. Sarwar, N.; Gao, P.; Seshasai, S.R.; Gobin, R.; Kaptoge, S.; Di Angelantonio, E.; Ingelsson, E.; Lawlor, D.A.; Selvin, E.; Stampfer, M.; et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375, 2215–2222. [CrossRef]
7. Koye, D.N.; Magliano, D.J.; Nelson, R.G.; Pavkov, M.E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 2018, 25, 121–132. [CrossRef]
8. Abramson, M.J.; Walters, J.; Walters, E.H. Adverse effects of beta-agonists: Are they clinically relevant? Am. J. Respir. Med. 2003, 2, 287–297. [CrossRef]
9. Noh, H.; Yu, M.R.; Kim, H.J.; Lee, J.H.; Park, B.W.; Wu, I.H.; Matsumoto, M.; King, G.L. Beta 2-adrenergic receptor agonists are novel regulators of macrophage activation in diabetic renal and cardiovascular complications. Kidney Int. 2017, 92, 101–113. [CrossRef]
10. Kwon, S. Thirty years of national health insurance in South Korea: Lessons for achieving universal health care coverage. Health Policy Plan. 2009, 24, 63–71. [CrossRef]
11. Yoon, C.Y.; Noh, J.; Jhee, J.H.; Chang, T.I.; Kang, E.W.; Kee, Y.K.; Kim, H.; Park, S.; Yun, H.R.; Jung, S.Y.; et al. Warfarin use in patients with atrial fibrillation undergoing hemodialysis: A nationwide population-based study. Stroke 2017, 48, 2472–2479. [CrossRef]
12. Baraka, A.M.; Darwish, I.E.; Ghoneim, M.T.; Korayem, H.K. beta2-Adrenoceptor agonists as potential therapeutic drugs in diabetic peripheral neuropathy. *Eur. J. Pharm.* 2015, 746, 89–95. [CrossRef]

13. Mishra, P.K.; Givvimani, S.; Metreveli, N.; Tyagi, S.C. Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. *Biochem. Biophys. Res. Commun.* 2010, 401, 175–181. [CrossRef]

14. Hayashi, T.; Juliet, P.A.; Miyazaki-Akita, A.; Funami, J.; Matsui-Hirai, H.; Fukatsu, A.; Iguchi, A. Beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes. *Life Sci.* 2007, 80, 592–599. [CrossRef]

15. Cazzola, M.; Calzetta, L.; Bettoncelli, G.; Cricelli, C.; Romeo, F.; Matera, M.G.; Rogliani, P. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. *Respir. Med.* 2012, 106, 249–256. [CrossRef]

16. Man, S.F.; Van Eeden, S.; Sin, D.D. Vascular risk in chronic obstructive pulmonary disease: Role of inflammation and other mediators. *Can. J. Cardiol.* 2012, 28, 653–661. [CrossRef]

17. Mandal, P.; Chalmers, J.D.; Choudhury, G.; Akram, A.R.; Hill, A.T. Vascular complications are associated with poor outcome in community-acquired pneumonia. *QJM* 2011, 104, 489–495. [CrossRef]

18. Warren-Gash, C.; Smeeth, L.; Hayward, A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: A systematic review. *Lancet Infect. Dis.* 2009, 9, 601–610. [CrossRef]

19. Clayton, T.C.; Thompson, M.; Meade, T.W. Recent respiratory infection and risk of cardiovascular disease: Case-control study through a general practice database. *Eur. Heart J.* 2008, 29, 96–103. [CrossRef]

20. Chew, S.K.; Colville, D.; Canty, P.; Hutchinson, A.; Wong, A.; Luong, V.; Wong, T.Y.; McDonald, C.; Savige, J. Hypertensive/microvascular disease and COPD: A case control study. *Kidney Blood Press. Res.* 2016, 41, 29–39. [CrossRef]

21. Oncel, C.; Baser, S.; Cam, M.; Akdag, B.; Taspinar, B.; Evyapan, F. Peripheral neuropathy in chronic obstructive pulmonary disease. *COPD* 2010, 7, 11–16. [CrossRef]

22. Kim, M.Y.; Boo, S.; Yoo, M.; Lee, J.; Kang, N.R. Impact of chronic kidney disease among Korean adults with chronic obstructive pulmonary disease. *Int. Urol. Nephrol.* 2017, 49, 1225–1232. [CrossRef]

23. Brownrigg, J.R.; de Lusignan, S.; McGovern, A.; Hughes, C.; Thompson, M.M.; Ray, K.K.; Hinchliffe, R.J. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. *Heart* 2014, 100, 1837–1843. [CrossRef]

24. Tuomilehto, J.; Borch-Johnsen, K.; Molarius, A.; Forsen, T.; Rastenyte, D.; Sarti, C.; Reunanen, A. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. *Diabetologia* 1998, 41, 784–790. [CrossRef]

25. Van Hecke, M.V.; Dekker, J.M.; Stehouwer, C.D.; Polak, B.C.; Fuller, J.H.; Sjolie, A.K.; Kofinis, A.; Rottiers, R.; Porta, M.; Chaturvedi, N.; et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: The EURODIAB prospective complications study. *Diabetes Care* 2005, 28, 1383–1389. [CrossRef]

26. Gordin, D.; Harjutsalo, V.; Tinsley, L.; Fickweiler, W.; Sun, J.K.; Forsblom, C.; Amenta, P.S.; Fober, D.; D’Eon, S.; Khatri, M.; et al. Differential association of microvascular attributions with cardiovascular disease in patients with long duration of Type 1 diabetes. *Diabetes Care* 2018, 41, 815–822. [CrossRef]

27. Lovshin, J.A.; Bjornstad, P.; Lovblom, L.E.; Bai, J.-W.; Lytvyn, Y.; Boulet, G.; Farooqi, M.A.; Santiago, S.; Orszag, A.; Sacc, D.; et al. Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. *Diabetes Care* 2018, 41, 2570. [CrossRef]

28. Aljunid, S.M.; Srithamrongswat, S.; Chen, W.; Bae, S.J.; Pwu, R.F.; Ikeda, S.; Xu, L. Health-care data collecting, sharing, and using in Thailand, China mainland, South Korea, Taiwan, Japan, and Malaysia. *Value Health* 2012, 15, S132–S138. [CrossRef]